#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Nephroblastoma Neuroendocrine carcinoma metastatic Diffuse large B-cell lymphoma refractory Adult T-cell lymphoma/leukaemia refractory Familial haemophagocytic lymphohistiocytosis Essential thrombocythaemia Lymphoma Osteogenesis imperfecta Pituitary-dependent Cushing's syndrome Endometrial cancer recurrent Liposarcoma recurrent Hepatic cirrhosis Oropharyngeal squamous cell carcinoma Leukocyte adhesion deficiency type I Hypocalcaemia More trials…

    Learn about Rare Diseases

    Paroxysmal nocturnal haemoglobinuria – Life with Disease Krabbe’s disease – Diagnostics Pulmonary fibrosis – Basic Information Myelodysplastic syndrome – Treatment Stevens-Johnson syndrome – Basic Information Synovial sarcoma metastatic – Trials in Disease Burkitt’s lymphoma – Treatment KBG syndrome – Treatment Prader-Willi syndrome Pulmonary sarcoidosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eteplirsen Guanabenz Acetate Ima203Cd8 Pegaspargase Vsf1.01 Mrna-4157 Ozanimod METAMIZOLE SODIUM Fluticasone Propionate Necvax-Neo1 Vimseltinib Risdiplam Gilteritinib Nesolicaftor Dimethyl Fumarate Mirvetuximab Soravtansine VELPATASVIR Paxalisib Ttf-Ngr Octreotide Acetate More therapies…

    Learn about Your Condition

    Partial seizures Rectal adenocarcinoma Rhabdomyosarcoma Thyroid cancer metastatic Viral infection Salivary gland cancer Inflammation Influenza Appendicitis Staphylococcal bacteraemia Atrial septal defect Intermittent claudication Oral lichen planus Hypoparathyroidism Peptostreptococcus infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

White matter lesion

  • Study on the Safety and Effects of Fosigotifator in Adults and Children with Vanishing White Matter Disease

    Recruiting

    1 1 1
    Investigated Diseases:
    • White matter lesion
    Investigated Drugs:
    • Sodium ({(2S)-1,4-Bis[2-(4-Chloro-3-Fluorophenoxy)Acetamido]Bicyclo[2.2.2]Octan-2-Yl}Oxy)Methyl Hydrogen Phosphate-2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol (1/1/1)
    The Netherlands

  • Study on the Safety and Tolerability of Guanabenz in Children with Vanishing White Matter Disease

    Not recruiting

    1 1 1
    Investigated Diseases:
    • White matter lesion
    Investigated Drugs:
    • Guanabenz Acetate
    The Netherlands

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!